Search | Clinical Trials Finder

Conditions: Eosinophilic Asthma
Interventions: ICS-LABA, benralizumab, Placebo for Benralizumab; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 34
States / cities: Chandler, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more

Conditions: Osteoarthritis, Knee
Interventions: Bone Marrow Derived MSCs, Corticosteroid, Bone Marrow Aspirate; Biological · Drug · Device
Lead sponsor: Next Generation Regenerative Medicine LLC; Network
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Chesterfield, Missouri • Steubenville, Ohio • Salt Lake City, Utah

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Back Pain
Interventions: Epidural steroid, Clonidine; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Systemic Lupus Erythematosus
Interventions: Prednisone, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 13 Years to 65 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 3
States / cities: New Hyde Park, New York • New York, New York • The Bronx, New York

Conditions: Knee Osteoarthritis
Interventions: Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline; Device · Drug
Lead sponsor: Dustin L. Richter, MD; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Nervous System Disease, Genetic Syndrome
Interventions: EryDex Low dose DSP, EryDex High dose DSP, Pooled Placebo; Drug
Lead sponsor: Quince Therapeutics S.p.A.; Industry
Eligibility: 6 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more

Conditions: Esophageal Squamous Cell Carcinoma
Interventions: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU), Oxaliplatin, Sacituzumab tirumotecan, Rescue Medication; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: Prednisone, Placebo; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 3 Years to 6 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Knee Osteoarthritis
Interventions: BioD Restore, Kenalog; Device · Drug
Lead sponsor: The Hawkins Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Greenville, South Carolina

Conditions: Asthma
Interventions: Symbicort pMDI, budesonide pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 12,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 160
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 157 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 84
States / cities: Surprise, Arizona • Little Rock, Arkansas • Los Angeles, California + 77 more

Conditions: Lupus Nephritis
Interventions: Obinutuzumab, Placebo, Mycophenolate Mofetil, Acetaminophen/paracetamol, Diphenhydramine hydrochloride (HCl), Methylprednisolone, Prednisone; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Asthma
Interventions: GP MDI, BFF MDI, Placebo MDI; Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 15
States / cities: Bakersfield, California • Lancaster, California • Long Beach, California + 12 more

Conditions: Hemorrhoids
Interventions: Monad 1, Monad 2, Monad 3, Combination - CITI-002 (low dose), Combination - CITI-002 (high dose); Drug
Lead sponsor: Citius Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 16
States / cities: Huntsville, Alabama • Tucson, Arizona • Chula Vista, California + 12 more

Conditions: Asthma
Interventions: Vitamin D3, Ciclesonide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 408 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 16
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 10 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 54
States / cities: Anniston, Alabama • Jasper, Alabama • Glendale, Arizona + 46 more

Conditions: Osteoarthritis, Post-traumatic; Arthrosis
Interventions: methylprednisolone acetate, active comparator; Drug
Lead sponsor: New Lexington Clinic; Other
Eligibility: 18 Years to 95 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Chronic Sinusitis
Interventions: Sinus Stent with drug coating, Non Coated Sinus Stent; Device
Lead sponsor: Intersect ENT; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 11
States / cities: Fresno, California • Colorado Springs, Colorado • Chicago, Illinois + 8 more

Conditions: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: LY3650150, Placebo, Standard therapy for INCS; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years and older
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 32 more

Conditions: Asthma
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 21
States / cities: Birmingham, Alabama • Glendale, Arizona • San Jose, California + 18 more

Conditions: Renal Transplantation
Interventions: Corticosteroid withdrawal; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rotator Cuff Tear, Rotator Cuff Tendinitis
Interventions: Adipose Derived Regenerative Cells, Corticosteroid; Device · Drug
Lead sponsor: InGeneron, Inc.; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • La Mesa, California • Pasadena, California + 11 more

Search by objective public record fields.

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

Mesenchymal Stem Cell Therapy for Knee Osteoarthritis

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Epidural Clonidine Versus Corticosteroid for Low Back Pain

Serologically Active, Clinically Stable Systemic Lupus Erythematosus

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia Patients

Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)

A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics

Steroid Injection vs. BioDRestore for Patients With Knee OA

A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids

Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma

Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks

Do Corticosteroid Injections During Total Knee Replacement Improve Early Clinical Results?

A Clinical Evaluation of a Steroid-Coated Sinus Stent When Used Following Functional Endoscopic Sinus Surgery in Patients With Chronic Sinusitis

A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP)

Efficacy and Safety Study of Benralizumab Added to Medium-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma

MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal

Autologous Adult Adipose-Derived Regenerative Cell Injection Into Chronic Partial-Thickness Rotator Cuff Tears